Calibration of HCV working reagents for NAT assays against the HCV international standard

被引:61
作者
Saldanha, J
Heath, A
Lelie, N
Pisani, G
Nübling, M
Yu, M
机构
[1] Natl Inst Biol Stand & Controls, Div Virol, S Mimms EN6 3QG, Herts, England
[2] Natl Inst Biol Stand & Controls, Div Informat, S Mimms EN6 3QG, Herts, England
[3] Netherlands Blood Transfus Serv, Cent Lab, Amsterdam, Netherlands
[4] Ist Super Sanita, Immunol Lab, I-00161 Rome, Italy
[5] Paul Ehrlich Inst, D-6070 Langen, Germany
[6] US FDA, CBER, Div Hematol, Rockville, MD 20857 USA
关键词
D O I
10.1159/000031184
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objectives: Five HCV RNA reference reagents, the Paul Ehrlich Institut (PEI) reference 75, the National Institute for Biological Standards and Control (NIBSC) reagent 96/586, the Central Laboratory of the Netherlands Red Cross Blood Transfusion Service (CLB) Pelispy HCV RNA run control S2001, the Istituto Superiore di Sanita (ISS) reagent 0498 and the CBER panel member No. 1,were calibrated against the WHO International Standard, 96/790. Materials and Methods: The reference materials were calibrated in a collaborative study organised by NIBSC. Nineteen laboratories, using a range of qualitative and quantitative assays returned results. Results: The concentrations of the reagents were: 25,000 IU/ml for the PEI material, 710 IU/ml for the NIBSC material 96/586, 1,000 IU/ml for the CLB material, 1,700 IU/ml for the ISS material 0498 and 250 IU/ml for the CBER panel member No. 1. Conclusions: The calibration of these five reference reagents for HCV RNA nucleic acid amplification technology (NAT) assays enables them to be used for standardisation and validation of assays. Such calibrants are essential for meeting the requirements of the European Medicinal Evaluation Agency (EMEA) for the testing of plasma pools and donations for HCV RNA for the release of blood products and the PEI requirements for the release testing of erythrocyte and thrombocyte concentrates. Copyright (C) 2000 S. Karger AG, Basel.
引用
收藏
页码:217 / 224
页数:8
相关论文
共 9 条
[1]  
Collet D, 1991, MODELLING BINARY DAT
[2]  
DAMEN M, 1997, VIRAL HEPATITIS LIVE
[3]   Accurate quantification of hepatitis C virus (HCV) RNA from all HCV genotypes by using branched-DNA technology [J].
Detmer, J ;
Lagier, R ;
Flynn, J ;
Zayati, C ;
Kolberg, J ;
Collins, M ;
Urdea, M ;
SanchezPescador, R .
JOURNAL OF CLINICAL MICROBIOLOGY, 1996, 34 (04) :901-907
[4]  
FRANCIS B, 1993, GLIM SYSTEM
[5]  
*GEN AMPL TECHN GA, 1997, CPMPBWP39097 GEN AMP
[6]   Comparison of plasma virus loads among individuals infected with hepatitis C virus (HCV) genotypes 1, 2, and 3 by Quantiplex HCV RNA assay versions 1 and 2, Roche monitor assay, and an in-house limiting dilution method [J].
Hawkins, A ;
Davidson, F ;
Simmonds, P .
JOURNAL OF CLINICAL MICROBIOLOGY, 1997, 35 (01) :187-192
[7]  
Nübling CM, 1998, INFUSIONSTHERAPIE, V25, P86
[8]   Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA [J].
Saldanha, J ;
Lelie, N ;
Heath, A .
VOX SANGUINIS, 1999, 76 (03) :149-158
[9]   Collaborative study to assess the suitability of an HCV RNA reference sample for detection of an HCV RNA in plasma pools by PCR [J].
Saldanha, J ;
Minor, P .
VOX SANGUINIS, 1996, 70 (03) :148-151